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More than 1900 different mutations in the CFTR gene have been reported. These are grouped into classes according to their effect on the
synthesis and/or function of the CFTR protein. CFTR repair therapies that are mutation or mutation class speciﬁc are under development. To
progress efﬁciently in the clinical phase of drug development, knowledge of the relative frequency of CFTR mutation classes in different
populations is useful. Therefore, we describe the mutation class spectrum in 25,394 subjects with CF from 23 European countries.
In 18/23 countries, 80% or more of the patients had at least one class II mutation, explained by F508del being by far the most frequent mutation.
Overall 16.4% of European patients had at least one class I mutation but this varied from 3 countries with more than 30% to 4 countries with less
than 10% of subjects. Overall only respectively 3.9, 3.3 and 3.0% of European subjects had at least one mutation of classes III, IV and V with again
great variability: 14% of Irish patients had at least one class III mutation, 7% of Portuguese patients had at least one class IV mutation, and in 6
countries more than 5% of patients had at least one class V mutation.
© 2013 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: CFTR mutations; Cystic ﬁbrosis; Genotype; Prevalence; CFTR mutation classes; Allele frequency1. Introduction
Cystic fibrosis (CF) (MIM# 219700) is a life-shortening
hereditary disease with relentless pulmonary infection and
malabsorption as the main symptoms. The disease is caused by
mutations in the Cystic Fibrosis Transmembrane Conductance
Regulator (CFTR) gene (MIM# 602421) coding for the CFTR
protein that functions as an anion channel. For a conciseAbbreviations: CF, Cystic Fibrosis; CFTR, Cystic Fibrosis Transmembrane
Conductance Regulator; ECFSPR, European Cystic Fibrosis Society Patien
Registry; PTC, premature termination codon.
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fax: +32 16 34 38 17.
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;lisheddescription of the disease we refer to Proesmans et al. [1].
Considerable progress in CF care has been made in the past
decades [2,3]. For patients with CF born in the United Kingdom
(UK) in the years 2000 to 2003, the median life expectancy was
estimated at 40 years [4]. However, as patients with CF live
longer, for most of them the quality of life worsens [5] and the
treatment burden [6] and cost [7] increase. More effective
treatments are thus critically needed.
More than 1900 CFTR mutations have been reported, of
which at least 1500 are considered potentially CF-causing since
they are reported in subjects with symptoms characteristic of
CF [8]. Many papers have pointed out regional differences in
prevalence of specific mutations and much of that information
was compiled and reported by Bobadilla et al. [9].
Grouping CFTR mutations into classes according to the
molecular mechanism by which the mutation disrupts normalby Elsevier B.V. All rights reserved.
Table 1
List of mutations by mutation class.
Class Type of defect List of mutations attributed to this class
Class I Defective protein
production
Nonsense mutations
Large deletions and insertions
1078delT; 1717-1G→A; 3659delC;
621+1G→T
Class II Defective protein
processing
G85E, F508del, I507del, R560T,
N1303K
Class III Defective protein
regulation (‘gating’)
G178R, S549N, S549R, G551D, G551S,
G970R, G1244E, S1251N, S1255P,
G1349D
Class IV Defective protein
conductance
R117H, R334W, R347P
Class V Reduced amount of
functioning protein
2789+5G→A, 3849+10KbC→T,
A455E
Unclassified All other mutations, including those
unknown.
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view of developing CFTR repair therapies. In addition, the type
of mutation class can partially explain the wide variation in
disease severity seen among patients with CF [10–13]. Under
most functional classifications, CFTR mutations are divided into
5 classes [10,11]. Mutations that result in a truncated and mostly
non-functional protein are categorized as class I. They include:
nonsense CFTR mutations (also called stop or premature ter-
mination codon (PTC) mutations); frame-shift mutations; large
deletions and insertions; splice-site mutations causing frame
shifts which often introduce a PTC. Class II mutations (including
the most common F508del mutation) lead to an aberrantly folded
CFTR protein that is targeted by the cell quality control
mechanism for degradation at the proteasome, resulting in the
near-absence of mature CFTR protein at the apical cell
membrane. Class III mutations lead to full-length CFTR protein
incorporated into the cell membrane, but with a defective
regulation (also called gating) so that no chloride ions flow
through the CFTR channel. CFTR mutations leading to reduced
conductance are grouped into class IV. Finally, class V
mutations result in a markedly decreased amount of CFTR
protein with normal function at the epithelial cell membrane and
include splice site mutations that only partially disturb correct
splicing (e.g. 3849+10KbCNT and 2789+5GNA) or mutant
CFTR that only partially matures (e.g. A455E).
Since the discovery of the CFTR gene more than 2 decades
ago, vast knowledge has been acquired in CFTR translational
medicine. Therefore, the hope to interfere with the basic defect
in the clinical setting and thus significantly alter the natural
course of the disease is now perceived as a realistic goal
[14,15]. Ivacaftor, a potent CFTR channel potentiator, is the
first mutation specific drug on the market that improves the
clinical status in patients with CF carrying at least one G551day
mutation [16] or at least one of the other class III mutations
[17]. Other mutation class specific treatments are in the pipeline
[18]: stop codon read through drugs for patients with premature
stop codon mutations, combination therapy with correctors and
potentiators in subjects with class II mutations, evaluation of
the efficacy of the CFTR potentiator ivacaftor in subjects with
R117H class IV mutation or residual CFTR function.
Up till now, papers that analyzed data from CF registries have
mainly explored the association between mutation class and
disease severity: indeed, having at least one mutation of class IV
or V is associated with a lower risk of being pancreatic in-
sufficient, and on average a better lung function and survival
[12,13]. These papers do not discuss the relative frequency of
mutation classes in different countries. CF registry reports also
do not report on relative frequency of mutation classes but
present demographic data and clinical data as well as relative
frequencies of specific CFTR mutations in individual countries.
In recent years however, knowing the geographic distribution of
mutation classes has become of interest, because drug develop-
ment proceeds to a large extent in a mutation class specific way
[18]. The clinical phases of drug development require testing
new compounds in a group of subjects with a specific mutation
or mutation class. These phases can only be efficient if clinical
trials are preferentially directed to countries or regions wherethese mutation classes are prevalent. The current paper therefore
reports the spectrum of the CFTR mutation classes in more than
25,000 European patients with CF.2. Methods
The 2009 (latest data update at time of writing) the European
Cystic Fibrosis Society Patient Registry (ECFSPR) data were
analyzed. The ECFSPR contains data from the national
registries of Belgium, Czech Republic, Germany, Denmark,
France, Hungary, Ireland, Israel, Moldova, The Netherlands,
Sweden, UK and from individual CF centers in Austria,
Switzerland, Greece, Spain, Italy, Latvia, Portugal, Serbia,
Slovenia, Bulgaria, and the Republic of Belarus. To evaluate
the representativeness of this data collection, we compared the
number of patients reported in the ECFSPR to the number of
patients with CF as reported by Farrell for several European
countries [19] and as estimated from the paper by Efrati et al.
[20] for Israeli patients.
We used CFTR mutation legacy names and converted all
other ways to refer to the same mutation into this nomenclature.
Obvious spelling mistakes were corrected according to the
database provided by the CFTR1 project available on-line [8].
CFTR mutations were then grouped into 5 mutation classes as
outlined in Table 1. We modified the classification proposed by
McKone et al. [21] based on new insights: G85E was reassigned
to class II [22], and recently recognized gating mutations with
proof of CFTR potentiator responsiveness were added to class III
[23]. Like McKone, we assigned all PTC mutations to class I.
All other mutations were grouped as mutation class unclassified.
The percentage of patients homozygous or heterozygous for
mutation classes I to V was then calculated on the European and
on the national level. Ninety five percent confidence intervals
were determined. If these did not overlap, differences in
occurrence were considered statistically significant. Since for
class I, only the subgroup with nonsense mutations is currently
targeted with specific drug therapy [18], we also reported this
405K. De Boeck et al. / Journal of Cystic Fibrosis 13 (2014) 403–409subgroup separately. When computing these percentages,
patients who do not carry 2 mutations belonging to the same
class, are represented twice. Therefore, the number of patients
with specific combinations of mutation classes are also reported.
3. Results
In Table 2 we list the number of patients reported in the
ECFSPR in participating countries and compare them to the
number of patients with CF as reported in several European
countries [19,20]. There are obvious differences in representa-
tiveness between countries. In Table 2 data are put in italics and
in Fig. 1 country names are put in a shaded area when less than
70% of estimated patients in that country were included in the
ECFSPR or when the number of patients was lower than 100.
CFTR genotype information was available for 25,394 of
26,685 (95.2%) patients. Therefore, 25,394 was used as denom-
inator when reporting the % of patients with at least one
mutation of a specific mutation class. In total 50,788 alleles were
thus examined (Table 2). In 46,441 alleles (91.4%), a CFTR
mutation was identified and 42,388 of these (91.3% of the
identified mutations) were classified into one of the 5 mutation
classes.
The percentage of alleles with mutations unidentified after
DNA analysis varied between countries: overall, 8.6% of
mutations remained unknown, but the proportion of undetectedTable 2
Number of patients and data contribution by country.
Country Number of
patients reported
in the literature
Number of
patients reported
to the ECFSPR
Number of patients
with DNA analysis
performed (%) a
Total 26,685 25,394 (95.16)
Austria (AT) 686 352 352 (100.0)
Belgium (BE) 1065 1129 1107 (98.0)
Bulgaria (BG) 170 95 95 (100.0)
Republic of Belarus (BY) – 145 141 (97.2)
Switzerland (CH) – 190 189 (99.5)
Czech Republic (CZ) 570 507 507 (100.0)
Germany (DE) 6835 5048 4534 (89.8)
Denmark (DK) 412 451 451 (100.0)
Spain (ES) 2200 740 739 (99.9)
France (FR) 4533 5640 5473 (97.0)
Greece (GR) 555 92 89 (96.7)
Hungary (HU) 410 555 555 (100.0)
Ireland (IE) 1182 1090 1042 (95.6)
Israel (IL) 507 533 530 (99.4)
Italy (IT) 5064 539 519 (96.3)
Latvia (LV) 24 29 29 (100.0)
Moldova (MD) – 41 41 (100.0)
The Netherlands (NL) 1275 1249 1179 (94.4)
Portugal (PT) 285 117 115 (98.3)
Serbia (RS) – 122 104 (85.2)
Sweden (SE) 362 578 578 (100.0)
Slovenia (SI) 66 66 66 (100.0)
United Kingdom (UK) 8284 7377 6959 (94.3)
Country data in italic means that the data from that country cover less than 70% of
a Percentage was computed using as denominator the number of patients reported
b Percentage was computed using as denominator the number of patients for who
c Percentage was computed using as denominator the number of alleles for whichmutations ranged from 1% in Denmark to 46.9% in Hungary.
However, in 14/23 countries less than 10% of alleles remained
unknown (Table 2).
Fig. 1 shows the percentage of CF patients who are
homozygous (darker color) or heterozygous (lighter color) for a
specific mutation class. In Fig. 1A percentages are given for all
class I mutations. In Europe overall, 3195 patients (12.6%) were
reported to be compound heterozygous or homozygous for a
nonsense mutation (Fig. 1B). The percentage of these patients
was remarkably higher in Israel (45.5%, 95%CI: 41.2; 49.8), Italy
(32.4%, 95%CI: 28.4; 36.6) and Slovenia (27.3%, 95%CI: 17.0;
39.6). Overall 22,144 European patients (87.2%) carried at least
one class II mutation (Fig. 1C): 9147 in heterozygosity and
12,997 in homozygosity. Their proportion was higher in
Denmark (97.1%, 95%CI: 95.1; 98.5), Latvia (96.5%, 95%CI:
82.2; 99.9), Ireland (94.6%, 95%CI: 93.1; 95.9), Serbia (94.2%,
95%CI: 87.9; 97.8), and lower in Israel (46.8%, 95%CI: 42.5;
51.1), Hungary (57.30%, 95%CI: 53.1, 61.4) and Italy (73.0%,
95%CI: 69.0; 76.8). Since the frequency of F508del greatly
outnumbered the frequency of all other class II mutations, the
proportion of patients carrying at least one class II mutation was
almost identical to the proportion of patients carrying F508del on
at least one allele (Fig. 1C and d). Jointly all ten gating mutations
were found in only 990 patients in Europe (3.9%). There was a
higher prevalence of patients carrying at least one class III
mutation in Ireland (13.9%, 95%CI: 11.9; 16.2), UK (6.2%,Number of patients
with 2 mutations
identified (%) b
Number of patients
with 1 mutation
identified (%) b
Number of
alleles
unknown (%) c
Number of alleles
classified into
classes I–V (%) c
21,958 (86.47) 2525 (9.94) 4347 (8.56) 42,388 (83.46)
312 (88.64) 28 (7.95) 52 (7.39) 602 (85.51)
987 (89.16) 91 (8.22) 149 (6.73) 1874 (84.64)
84 (88.42) 11 (11.58) 11 (5.79) 153 (80.53)
97 (68.79) 44 (31.21) 44 (15.60) 222 (78.72)
181 (95.77) 7 (3.7) 9 (2.38) 323 (85.45)
483 (95.27) 17 (3.35) 31 (3.06) 882 (86.98)
3397 (74.92) 710 (15.66) 1564 (17.25) 7080 (70.08)
443 (98.23) 7 (1.55) 9 (1.00) 833 (92.35)
575 (77.81) 143 (19.35) 185 (12.52) 1095 (74.09)
5292 (96.69) 181 (3.31) 181 (1.65) 9331 (85.24)
67 (75.28) 18 (20.22) 26 (14.61) 141 (79.21)
241 (43.42) 108 (19.46) 520 (46.85) 565 (50.90)
975 (93.57) 65 (6.24) 69 (3.31) 1914 (91.84)
372 (70.19) 78 (14.72) 238 (22.45) 692 (65.28)
469 (90.37) 46 (8.86) 54 (5.20) 833 (80.25)
18 (62.07) 11 (37.93) 11 (18.97) 45 (77.59)
33 (80.49) 6 (14.63) 10 (12.20) 60 (73.17)
1112 (94.32) 52 (4.41) 82 (3.48) 2188 (92.79)
110 (95.65) 5 (4.35) 5 (2.17) 193 (83.91)
84 (80.77) 18 (17.31) 22 (10.58) 178 (85.58)
559 (96.71) 14 (2.42) 24 (2.08) 931 (80.54)
59 (89.39) 6 (9.09) 8 (6.06) 112 (84.85)
6008 (86.33) 859 (12.34) 1043 (7.49) 12,141 (87.23)
the estimated total patient number or concerns less than 100 patients.
to the ECFSPR.
m DNA analysis was performed.
DNA analysis was performed.
A Percent of patients with 1 or 2 class Imutations
D Percent of patients with 1 or 2 F508delmutations
B Percent of patients with 1 or 2 nonsense mutations
C Percent of patients with 1 or 2 class IImutations
Fig. 1. Percentage of European patients (N = 25,394) carrying one (lighter shade) or two (darker shade) mutations of a specific mutation class, by country and in total cohort. Panel A shows class I, panel B shows
nonsense mutations, panel C shows class II, panel D shows mutation F508del, panel E shows class III, panel F shows class IV, panel G shows class V. AT: Austria, BE: Belgium, BY: Republic of Belarus, BG:
Bulgaria, CH: Switzerland, CZ: Czech Republic, DE: Germany, DK: Denmark, ES: Spain, FR: France, GR: Greece, HU: Hungary, IE: Ireland, IL: Israel, IT: Italy, LV: Latvia, MD: Republic of Moldova, NL: The
Netherlands, PT: Portugal, RS: Serbia, SE: Sweden, SI: Slovenia, UK: United Kingdom. Country name in italics in the legend above and in a shaded box in the figure means that the data from that country cover less
than 70% of the estimated total patient number or concerns less than 100 patients.
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E Percent of patients with 1 or 2 class IIImutations F Percent of patients with 1 or 2 Class IVmutations
G Percent of patients with 1 or 2 Class Vmutations
Fig. 1 (continued).
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Fig. 2. Distribution of CFTR mutation classes in European patients with CF. Each bar represents the number of CF patients with a specific mutation class
combination.
408 K. De Boeck et al. / Journal of Cystic Fibrosis 13 (2014) 403–40995%CI: 5.6; 6.8), the Czech Republic (4.7%, 95%CI: 3.1; 7.0)
and Belgium (3.6%, 95%CI: 2.6; 4.9) when compared with the
other countries, where the prevalence was below 3% (Fig. 1E).
Patients carrying at least one class IV mutation were also
uncommon: 833 were registered in the ECFSPR (3.3%), but their
proportion within countries was variable (Fig. 1F). Similarly,
patients carrying at least one class V mutation were uncommon:
762 (3.0%) were reported to the ECFSPR again concentrated in
specific countries (Fig. 1G).
The combination of mutation classes within patients is
shown in Fig. 2. The most frequent combination was by far
class II/class II (51.3%), followed by class I/class II (11.2%).
4. Discussion
We describe the CFTR mutation class frequency in a large
cohort of European patients with CF and show marked hetero-
geneity between countries. The variability in CFTR mutations
between countries has been documented before [9,24] and many
reports describe the increased frequency of mutations in specific
countries, but this report is the first to document the relative
frequency of mutation classes in a European population as well as
in specific countries. This is relevant for the development of CFTR
mutation class specific therapies, a new form of individualized
treatment aimed at correcting the basic CF defect.
Although patients with CF carry a wide spectrum of CFTR
mutations, class II mutations, because these contain F508del, are
by far the most frequent. According to the data available to the
ECFSPR, therapeutic approaches that address F508del may help
more than 80% of CF patients in most European countries. By
comparison all other CFTRmutations are relatively rare. Since the
ultimate aim is to develop treatments for all mutation categories, it
is important to know where the respective patients are mainly
found. The most useful example is the geographic distribution of
the G551day and other gating mutations reported in the current
paper. The CFTR potentiator ivacaftor has proven efficacy in
patients carrying the class III mutation G551day [16]. It has also
proven in vitro efficacy to potentiate other gating mutations [23]
and clinical benefit in patients with these mutations was also
recently shown [17]. Jointly, the 9 non-G551D gating mutations
account for only 18.3% of patients with a class III mutation.However, knowing the countries where patients with these
mutations reside is needed to provide them access to the drug.
Since ivacaftor also potentiates normal CFTR [23] clinical trials
are ongoing in subjects carrying class IV or V mutations, other
mutation categories that differ considerably between countries.
The current report has limitations. Data representativeness
differs between countries and therefore also the correctness of the
estimate of occurrence of a mutation class. This is pointed out in
Table 2 and in Fig. 1. Whereas in many long established national
registries coverage is high, in more recent national registries this
might not yet be the case and in some countries reporting is from
selected centers only. For further details on the representativeness
of data collection to the ECFSPR, we refer to the ECFSPR annual
report [25]. The difference in mutation class frequency between
countries reflects the known genetic diversity between countries
[9,24] but may also to some extent reflect differences in the
thoroughness of DNA analysis between countries and between
CF centers (Table 2). Furthermore, reliability of genetic analysis
may not be optimal in all centers [26]. Lastly, assigning a CFTR
mutation exclusively to one class is not entirely accurate, since
mutations may have properties of several mutation classes. A
fraction of F508del mutant CFTR is known to escape the cellular
quality control system and appear at the apical cell membrane
[27,28]. Such F508del-CFTR protein has however reduced
function since it has at most 20% of wild type CFTR activity
[29]. F508del thus combines the properties of class II and class
III–IV mutations. Non-maturing mutants when rescued by a
corrector may thus also behave as a class III or IV mutation. For
drug development this points towards the necessity to combine
CFTR correctors and potentiators. Patients carrying splice site
mutations that generate a new exon harboring a stop codon (e.g.;
3849+10kbCNT) may thus, like patients with nonsense muta-
tions, benefit similarly from treatment with drugs promoting
‘read-through’ of stop codons. Lastly, for many mutations it is
unknown to what mutation class they belong. The CFTR 2
project [30] was set up to fill this knowledge gap by investigating
the effect of mutations with a frequency above 0.01% on the
synthesis and function of the CFTR protein in vitro. This will thus
help further grouping of mutations in mutation classes.
In conclusion, the frequency of CFTR mutation classes varies
considerably between countries. In 18/23 countries, 80% or
409K. De Boeck et al. / Journal of Cystic Fibrosis 13 (2014) 403–409more of the patients had at least one class II mutation. Overall
16.4% of European patients had at least one class I mutation but
this varied from 3 countries with more than 30% to 4 countries
with less than 10% of subjects. Overall only respectively 3.9, 3.3
and 3.0% of European subjects had at least one mutation of
classes III, IV and V with again great variability: 14% of Irish
patients had at least one class III mutation, 7% of Portuguese
patients had at least one class IV mutation, and in 6 countries
more than 5% of patients had at least one class V mutation.
These differences reflect the known genetic heterogeneity, but
they might also to some degree be due to differences in detail of
genetic analysis between countries.
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